x

Cerca una sperimentazione clinica

* (*) campo obbligatorio

244 Risultato/i

Ordinato per

Sperimentazione in fase di reclutamento = Sperimentazione in fase di reclutamento
; Sperimentazione in corso = Sperimentazione in corso
; Finanziato da un ente associato a IRDiRC =

Sperimentazioni cliniche nazionali

GERMANIA

Baden-Württemberg
ULM

Sperimentazione in fase di reclutamento
Sperimentazione in corso
EMAA: Efficacy and Safety of Eltrombopag in Patients with Acquired Moderate Aplastic Anemia who are treated with Ciclosporin A (Phase II/III) - DE
DRK Baden-Württemberg/ Hessen
Institut für Klinische Transfusionsmedizin und Immungenetik Ulm

GERMANIA

Sachsen
DRESDEN

Sperimentazione in corso
A phase III, multicenter, randomised, double-blind, placebo-controlled study of Darbepoetin Alfa for the treatment of anaemic subjects with low or intermediate-1 risk Myelodysplastic Syndrome - DE
Universitätsklinikum Carl Gustav Carus an der TU Dresden
Medizinische Klinik und Poliklinik I - Fachbereich Hämatologie und Blutstammzelltransplantation

AUSTRIA

WIEN
WIEN

Sperimentazione in corso
A Phase 2 Study of LY2784544 in Patients with Myeloproliferative Neoplasms - AT
Allgemeines Krankenhaus der Stadt Wien
Klinische Abteilung für Hämatologie und Hämostaseologie

FRANCIA

BRETAGNE
BREST

Thalidomide treatment for agnogenic myeloid metaplasia (Phase II) - Terminated -
CHU de Brest - Hôpital de la Cavale Blanche
Laboratoire d'hématologie

FRANCIA

ILE-DE-FRANCE
PARIS

VPACS : Non Invasive Positive Pressure Ventilation for Prevention of Acute Chest Syndrome in Sickle Cell Disease With Vaso-occlusive Crisis and Morphinic Treatment
Hôpital Necker-Enfants Malades
Service de Réanimation et unités de soins continus médico-chirurgicale pédiatriques

FRANCIA

OUTRE-MER
FORT DE FRANCE

Efficacy and Safety of Bosentan in Sickle Cell Disease (SCD) Patients With Pulmonary Arterial Hypertension (PAH) (Phase III)
CHU de Martinique - Hôpital P. Zobda-Quitman
Cardiologie Pédiatrique et Congénitale

GERMANIA

Baden-Württemberg
HEIDELBERG

Sperimentazione in corso
MPN-SG 01-09 (MPN Pomalidomide): Multicenter Phase II Study with Pomalidomide in patients with Myeloproliferative Neoplasms in fibrotic Stage
Nationales Centrum für Tumorerkrankungen (NCT)
Nationales Centrum für Tumorerkrankungen (CCC) Heidelberg

GERMANIA

Hamburg
HAMBURG

Sperimentazione in fase di reclutamento
Sperimentazione in corso
Ruxolitinib versus allogeneic stem cell transplantation for patients with myelofibrosis according to donor availability: A prospective phase II trial (MMM 02 study) - DE
UKE - Universitätsklinikum Hamburg-Eppendorf
Interdisziplinäre Klinik und Poliklinik für Stammzelltransplantation

GERMANIA

Nordrhein-Westfalen
AACHEN

GERMANIA

Nordrhein-Westfalen
MINDEN

Sperimentazione in corso
JHTB(a): A Phase 2 Study of LY2784544 in Patients With Myeloproliferative Neoplasms - DE
Johannes Wesling Klinikum Minden
Klinik für Hämatologie, Onkologie und Palliativmedizin

PAESI BASSI

Gelderland
NIJMEGEN

PAESI BASSI

Noord-Holland
AMSTERDAM

Sperimentazione in corso
Microvascular Damage in Sickle Cell Disease
Amsterdam UMC, locatie AMC
Afdeling Hematologie

REGNO UNITO; GRAN BRETAGNA

Greater London
LONDON

REGNO UNITO; GRAN BRETAGNA

Greater Manchester
ADDRESS: NOT PROVIDED - UK

REGNO UNITO; GRAN BRETAGNA

Greater Manchester
ADDRESS: NOT PROVIDED - UK

REGNO UNITO; GRAN BRETAGNA

Greater Manchester
ADDRESS: NOT PROVIDED - UK

REGNO UNITO; GRAN BRETAGNA

West Midlands
BIRMINGHAM

SPAGNA

Madrid
ADDRESS: NOT PROVIDED - ES

STATI UNITI

Ohio
CINCINNATI

Sperimentazione in fase di reclutamento
Sperimentazione in corso
Finanziato da un ente associato a IRDiRCQuercetin in Children With Fanconi Anemia; a Pilot Study (Phase 1/2) - US
Cincinnati Children's Hospital Medical Center
Department of Pediatry

AUSTRIA

WIEN
ADDRESS: NOT PROVIDED - AT

FRANCIA

NOUVELLE AQUITAINE
PESSAC

ANEMIL : Phase I/II Clinical Trial Evaluating the Interest of Interleukine-2 for Patients With Active Warm Hemolytic Anemia Resistant to Conventional Treatment
CHU de Bordeaux-GH Sud - Hôpital Haut-Lévêque
Service de médecine interne et maladies infectieuses (Sud)

GERMANIA

Baden-Württemberg
HEIDELBERG

An open-label, multicentre controlled clinical trial of Eculizumab in adult patients with plasma therapy-resistant Atypical Hemolytic-Uremic Syndrome (aHUS) (Phase II) - DE
Zentrum für Kinder- und Jugendmedizin - Angelika-Lautenschläger-Klinik
Klinik für Kinderheilkunde I - Sektion Pädiatrische Nephrologie

GERMANIA

Baden-Württemberg
HEIDELBERG

An open-label, multicentre controlled clinical trial of Eculizumab in adult patients with plasma therapy-sensitive Atypical Hemolytic-Uremic Syndrome (aHUS) (Phase II) - DE
Zentrum für Kinder- und Jugendmedizin - Angelika-Lautenschläger-Klinik
Klinik für Kinderheilkunde I - Sektion Pädiatrische Nephrologie

GERMANIA

Baden-Württemberg
HEIDELBERG

An open-label, multicentre clinical trial of Eculizumab in pediatric patients with Atypical Hemolytic-Uremic Syndrome (aHUS) (Phase II) - DE- Completed
Zentrum für Kinder- und Jugendmedizin - Angelika-Lautenschläger-Klinik
Klinik für Kinderheilkunde I - Sektion Pädiatrische Nephrologie

ITALIA

EMILIA ROMAGNA
FERRARA

Sperimentazione in corso
Studio in aperto per valutare gli effetti a lungo termine di ACE-536 in pazienti con beta-talassemia precedentemente inseriti nello studio A536-04
A.O.U. di Ferrara - Nuovo Ospedale S.Anna - Sede di Cona
Day Hospital della Talassemia e delle Emoglobinopatie

ITALIA

LAZIO
ROMA

Studio clinico di fase 2, in doppio cieco, controllato con placebo, di EPI-743 in soggetti con deficit di cobalamina C
IRCCS Ospedale Pediatrico Bambino Gesù - SEDE SAN PAOLO
U.O.C. di Patologia Metabolica

ITALIA

LOMBARDIA
MILANO

Sperimentazione in fase di reclutamento
Sperimentazione in corso
Sperimentazione clinica multicentrica in aperto sull'utilizzo di eculizumab in pazienti pediatrici affetti da sindrome emolitico-uremica (SEU) atipica (Fase II).
IRCCS Ca' Granda - Ospedale Maggiore Policlinico - Clinica Pediatrica De Marchi
Centro per la Cura e lo Studio della Sindrome Emolitico Uremica (Center for HUS Control)

ITALIA

LOMBARDIA
PAVIA

Eltrombopag for Inherited Thrombocytopenias
Fondazione IRCCS Policlinico San Matteo
Clinica Medica III

PAESI BASSI

Gelderland
NIJMEGEN

REGNO UNITO; GRAN BRETAGNA

Greater London
LONDON

Sperimentazione in corso
An open-label, multi-center clinical trial of eculizumab in pediatric patients with atypical hemolytic-uremic syndrome (aHUS) (Phase II) - UK
University College London Hospitals, NHS Foundation Trust
Renal Office - Consultant Paediatric Nephrologist

REGNO UNITO; GRAN BRETAGNA

Greater Manchester
ADDRESS: NOT PROVIDED - UK

REGNO UNITO; GRAN BRETAGNA

Tyne & Wear
NEWCASTLE UPON TYNE

An open-label, multi-center controlled clinical trial of eculizumab in adult patients with plasma therapy-resistant Atypical Hemolytic-Uremic Syndrome (aHUS) (Phase II) - UK
Newcastle upon Tyne Hospitals NHS Trust
John Walton Muscular Dystrophy Research Centre, Institute of Genetic Medicine

REGNO UNITO; GRAN BRETAGNA

Tyne & Wear
NEWCASTLE UPON TYNE

An open-label, multi-center controlled clinical trial of eculizumab in adolescent patients with plasma therapy-resistant Atypical Hemolytic-Uremic Syndrome (aHUS) (Phase II) - UK
Newcastle upon Tyne Hospitals NHS Trust
John Walton Muscular Dystrophy Research Centre, Institute of Genetic Medicine

REGNO UNITO; GRAN BRETAGNA

Tyne & Wear
NEWCASTLE UPON TYNE

An open-label, multi-center controlled clinical trial of eculizumab in adult patients with plasma therapy-sensitive Atypical Hemolytic-Uremic Syndrome (aHUS) (Phase II) - UK
Newcastle upon Tyne Hospitals NHS Trust
John Walton Muscular Dystrophy Research Centre, Institute of Genetic Medicine

REGNO UNITO; GRAN BRETAGNA

Tyne & Wear
NEWCASTLE UPON TYNE

An open-label, multi-center controlled clinical trial of eculizumab in adolescent patients with plasma therapy-sensitive Atypical Hemolytic-Uremic Syndrome (aHUS) (Phase II) - UK
Newcastle upon Tyne Hospitals NHS Trust
John Walton Muscular Dystrophy Research Centre, Institute of Genetic Medicine

SPAGNA

Cataluña
BARCELONA

ITALIA

LOMBARDIA
BRESCIA

Ciclo breve di Bortezomib in pazienti anemici con crioagglutinemia refrattaria
ASST Spedali Civili di Brescia
U.O. di Ematologia

REGNO UNITO; GRAN BRETAGNA

Greater London
LONDON

Sperimentazioni cliniche internazionali

SPAGNA

Madrid
MADRID

Sperimentazione in corso
Finanziato da un ente associato a IRDiRCEUROFANCOLEN: Phase I/II Gene Therapy Trial of Fanconi anemia patients with a new Orphan Drug consisting of a lentiviral vector carrying the FANCA gene: A Coordinated International Action
CIEMAT - Centro de Investigaciones Energéticas Medioambientales y Tecnológicas
Terapias innovadoras en el sistema hematopoyético